Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2021 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $20.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax rose 7.32% year-over-year to $20.6 million, compared with a TTM value of $20.6 million through Sep 2025, up 7.32%, and an annual FY2025 reading of $20.6 million, up 7.32% over the prior year.
  • Long-Term Deferred Tax was $20.6 million for Q3 2025 at Neuroone Medical Technologies, up from $19.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $20.6 million in Q3 2025 and bottomed at $8.9 million in Q3 2021.
  • Average Long-Term Deferred Tax over 5 years is $15.3 million, with a median of $15.6 million recorded in 2023.
  • The sharpest move saw Long-Term Deferred Tax soared 35.9% in 2022, then rose 7.32% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $8.9 million in 2021, then skyrocketed by 35.9% to $12.1 million in 2022, then increased by 29.65% to $15.6 million in 2023, then grew by 22.59% to $19.2 million in 2024, then rose by 7.32% to $20.6 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for NMTC at $20.6 million in Q3 2025, $19.2 million in Q3 2024, and $15.6 million in Q3 2023.